Protein Antigens and Antigen-Presenting Cells surface

The interaction between protein antigens and the surface of antigen-presenting cells (APCs) is a fundamental process in the adaptive immune system (StatPearls, 2023). APCs, such as dendritic cells, macrophages, and B cells, internalize protein antigens, process them into smaller peptides, and display them on their surface via Major Histocompatibility Complex (MHC) molecules (Janeway's Immunobiology, 2001). This complex, along with co-stimulatory signals like CD80 and CD86, is recognized by T-cell receptors to initiate a specific immune response (Nature Reviews Immunology, 2005). In a therapeutic context, this interface represents the site of action for vaccines and immunotherapies designed to prime the immune system against pathogens or tumors. Conversely, it can be targeted to induce tolerance in autoimmune diseases or prevent transplant rejection by blocking co-stimulation (PubMed, 2021). Drugs like Sipuleucel-T utilize this interface by loading APCs with specific antigens to treat prostate cancer, while others like Abatacept modulate it to treat rheumatoid arthritis (FDA, 2010; NCBI, 2022). Because this term encompasses a variety of proteins and cellular interactions rather than a single molecule, it is classified as a biological pathway or interface. Monitoring biomarkers like HLA expression and CD80/86 levels is crucial for assessing the efficacy of treatments targeting this system. Safety concerns often involve over-activation of the immune system, leading to cytokine release syndrome or systemic autoimmunity.

Other names

Antigen presentation complexAPC-antigen interfaceMHC-peptide complexImmunological synapse (APC side)

Modulation of the immunological synapse through the presentation of peptide-MHC complexes and the regulation of co-stimulatory or co-inhibitory signals to T-lymphocytes (NCBI, 2022).